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Abstract
Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus
regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible.
We report the successful treatment of a premature infant with M. hominis meningitis with
doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.
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Mycoplasma hominis meningitis is an uncommon but life-threatening infection among
infants.1 Survivors frequently have long-term morbidity including severe
neurodevelopmental impairment. Mycoplasma species lack a cell wall, rendering them
resistant to agents such as penicillins and cephalosporins that are often used for empirical
therapy. In vitro testing has demonstrated susceptibility of M. hominis to chloramphenicol,
tetracyclines, lincosamides, and fluoroquinolones.2 Tetracyclines are often considered “first-
line” therapies, but are bacteriostatic and contraindicated in children because of their effect
on bones and teeth. Fluoroquinolones display marked intracellular accumulation and are
bactericidal against Mycoplasma species. Use of fluoroquinolones in infants and children
has been limited due to concern about cartilage damage.3 Moxifloxacin1 and
ciprofloxacin1, 4 are used to treat M. hominis meningitis in infants, but little is known about
their pharmacokinetics (PK) in this population.
We present the successful treatment of a case of M. hominis meningitis with doxycycline
and moxifloxacin in a preterm infant. Determination of moxifloxacin PK in our patient may
help inform future studies of the dosing and effects of moxifloxacin in infants.
CLINICAL CASE REPORT
An 813 g male infant was born at a regional hospital at 26 weeks gestation. Maternal
pregnancy history was otherwise unremarkable. The patient was intubated in the delivery
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room, and he received ampicillin, gentamicin, and ceftazidime for presumed sepsis.
Ceftazidime was stopped after 5 days of therapy, but ampicillin and gentamicin were
continued. He was successfully extubated on day of life 6, but the following day became
hypotonic, had a prolonged apneic episode, and displayed generalized tonic-clonic activity
concerning for a seizure. The patient was re-intubated, and on subsequent examination, was
noted to have a full fontanelle. A head ultrasound was obtained that demonstrated
hydrocephalus with blood in the ventricles consistent with a previous grade III
intraventricular hemorrhage. Cerebrospinal fluid (CSF) obtained via lumbar puncture
demonstrated 1920 white blood cells (WBC)/mm3 (86% polymorphonuclear cells and 14%
mononuclear cells); 6720 red blood cells (RBC)/mm3; and > 460 mg/dL of protein. CSF
glucose was not obtained. The patient was diagnosed with presumed meningitis, and
amphotericin B deoxycholate was added to the ampicillin and gentamicin therapy. The
ampicillin and gentamicin were discontinued on day of life 8 when the infant's regimen was
changed to vancomycin and acyclovir, followed by fluconazole on day of life 10, and
tobramycin and meropenem on day of life 12. These six antimicrobials were continued until
day of life 19 when he was transferred to our hospital for neurosurgical evaluation due to
worsening hydrocephalus. The initial CSF culture from day 6 of life was negative for
bacteria, and subsequent attempts at lumbar puncture were unsuccessful.
CSF obtained via ventricular tap at our institution on day of life 20 demonstrated 23,750
WBCs/mm3 (80% neutrophils, 7% lymphocytes, 6% monocytes). On day of life 24, the
infant had another ventricular tap which demonstrated 13,733 WBCs/mm3 (90%
neutrophils, 4% lymphocytes, and 6% monocytes), protein of 1960 mg/dL and glucose of <
20 mg/dL in the CSF. CSF from day of life 24 and 26 yielded M. hominis by 16s rRNA
sequencing. As a result of these findings, doxycycline (2 mg/kg IV Q 6 hours) and
moxifloxacin (5 mg/kg IV Q 24 hours) were started to complete a six week course.
Moxifloxacin dosing was recommended by our pediatric infectious disease consultants using
linear, weight-based extrapolation from adult dosing and based on the infant's current weight
of 1164g. The other antimicrobials were discontinued. A repeat ventricular tap after two
weeks of therapy demonstrated 6 WBC/mm3 (4% neutrophils, 20% lymphocytes, and 15%
monocytes), protein of 1309 mg/dL, glucose of 27 mg/dL, and no identification of M.
hominis in the CSF.
MATERIAL AND METHODS
The infant was enrolled in an off-label therapeutic study that was approved by The
University of North Carolina at Chapel Hill's Institutional Review Board. If an infant was
receiving an off-label therapeutic as part of clinical care, we collected PK samples during
times of routine blood draws and clinical information from the medical chart. The study did
not prescribe the therapeutic agent or the dose. We obtained written informed consent from
the patients’ parents.
Moxifloxacin was infused over 1 hour, and blood samples were collected around the 7th and
14th doses of moxifloxacin at the following time points: 0.7, 1.9, 17.5, and 22.1 hours after
end of infusion. Within 10 minutes of collection, 400 μL of whole blood was spun at 4000g
for 10 minutes and the plasma (~200 μL) was frozen at -80 °C until shipping. The samples
were shipped on dry ice to NorthEast BioAnalytical Laboratories (Hamden, CT) and
analyzed using a validated liquid chromatography-tandem mass spectrometry method for
simultaneous determination of moxifloxacin and its metabolites (M1 and M2) in plasma.
Drug extraction was performed by protein precipitation. The calibration range of the
Moxifloxacin ranged from 10 - 5000 ng/mL and for metabolites M1 and M2 ranged from 10
- 2500 ng/mL. Samples were analyzed in a single batch and the accuracy of all quality
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control (QC) samples ranged from 95 - 107%, and coefficient of variation (CV) ranged from
0.3 - 7.9%.
PK indices were calculated using non-compartmental methods5 with WinNonLin 6.1
(Pharsight, Cary, NC), assuming steady state and applying the superposition principle.
RESULTS
The concentration time profile for this infant compared with healthy adult volunteers is
presented in Figure 1.6 The maximum concentration (Cmax), area under the curve
(AUC0-24), and systemic clearance (CL) were 1.7 mg/L, 16.5 mg*h/L, and 0.3 L/h/kg,
respectively. The moxifloxacin concentration after 22 hours of drug administration was 0.18
mg/L. The Cmax and AUC0–24 for metabolites M1 and M2 were 1.2 mg/L, 17.8 mg*h/L and
1.5 mg/L, 22.2 mg*h/L, respectively.
DISCUSSION
This is the first report of moxifloxacin use in an infant where serial moxifloxacin
concentrations were obtained. In this case, moxifloxacin therapy was successful against M.
hominis meningitis. However, moxifloxacin PK parameters in our infant differed
substantially from those reported in healthy adult volunteers.7 Substantial PK differences
frequently exist between infants, children, and adults, often leading to treatment failure or
serious toxicity.8 With increased antibiotic pressure in neonatal and pediatric intensive care
units and the rise of resistant organisms, more agents considered “second-line” are used in
infants and children without PK studies to guide dosing.
Moxifloxacin, like other fluoroquinolones, exhibits concentration-dependent killing of
Gram-negative bacteria, and unlike some of the early-generation fluoroquinolones (e.g.
ciprofloxaxin), moxifloxacin also displays concentration-dependent killing of Gram-positive
organisms.9 Various pharmacodynamics (PD) endpoints have been studied in vitro and
clinically, and AUC24:minimum inhibitory concentration (MIC) and Cmax:MIC ratios are
the primary predictors of bacteriological eradication and clinical efficacy.10
The appropriate PD endpoint for atypical organisms such as M. hominis is unknown.
However, a full term infant with M. hominis meningitis was successfully treated with 13
mg/kg daily of oral moxifloxacin, in addition to ampicillin, cefotaxime, minocycline,
ciprofloxacin, chloramphenicol, and acyclovir.1 In that infant, the MIC of M. hominis for
moxifloxacin was 0.063 mg/L and after 3 days of moxifloxacin therapy, concentrations in
the serum and CSF were 0.30 mg/L and 0.16 mg/L, respectively.
The Cmax for our infant was ~1/3 of that described in adults.7 Based on existing MIC data
for M. hominis this should provide a Cmax:MIC ratio of 27; the concentration recorded 22
hours post dose (at the end of the dosing interval) was still 2.9 times greater than the
organism MIC. However, moxifloxacin concentrations in our infant would be sub-
therapeutic for many Gram positive and Gram negative organisms. This suggests higher
moxifloxacin doses may be required in this population and should be further explored.
The Cmax and AUC0-24 of metabolite M1 in our infant were 10 and 20 times greater,
respectively, than that reported in healthy adults after a single dose of intravenous
moxifloxacin.7 The Cmax and AUC0-24 of M2 were three times the levels measured in the
same adult population. Moxifloxacin is metabolized via sulfate conjugation (M1) and
glucuronidation (M2)7 and developmental ontogeny of these pathways or differences in
protein binding could account for the lower moxifloxacin concentrations observed. While
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moxifloxacin metabolites are inactive, higher rates of metabolism for drugs in which the
activity of metabolites is not known could make assessing the risk/benefit ratio difficult.
These PK data are limited by inclusion of only one infant and a limited number of PK data
points collected to derive PK parameters. Sampling was limited to scheduled draws, and
because our Cmax was recorded 0.7h after the end of the infusion, we may have
underestimated the Cmax and consequently the AUC0-24.
The PK of moxifloxacin in this infant differed substantially from that reported in healthy
adults, which suggests that linear, weight-based extrapolation of adult dosing in this setting
is inappropriate. This case also represents the successful collection and subsequent analysis
of an off-label therapeutic agent in an infant using a novel study design, and may provide a
model for the collection on PK data in these vulnerable children. In order to generalize these
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Moxifloxacin serum concentrations in an infant compared with adults * Adult data adapted
from Avelox® Label (Bayer Pharmaceuticals Corporation, Leverkusen, Germany).6
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